Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesFerritin for the clinicianRole of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in ChildrenInfections in myelodysplastic syndromesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyGuidelines on haemovigilance of post-transfusional iron overloadAllogeneic transplantation, Fas signaling, and dysregulation of hepcidinPharmacogenetic study of deferasirox, an iron chelating agentManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesThe prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromesPharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO studyLiver iron content determination by magnetic resonance imaging.From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.Hematopoietic stem cell transplantation for MDS.Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: Results of a meta-analysis of observational studies.Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis.Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.Increased serum iron levels and infectious complications after liver transplantation.Iron chelation therapy in myelodysplastic syndromes.Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantationSomatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationThe Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant OutcomesNew treatments for myelodysplastic syndromesUnrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.Clinical implications of chimerism after allogeneic hematopoietic stem cell transplantation in children with non-malignant diseasesDesign and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.Does iron overload really matter in stem cell transplantation?Current status of allogeneic hematopoietic cell transplantation for MDS.A Meta-Analysis for Effects of Elevated Pre-Transplantation Serum Ferritin on the Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplantation.Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.
P2860
Q24289511-4E47072D-5A6E-4AB1-AE3C-1C444353A208Q24642942-24FC18EB-BFF0-45F4-8A54-A0E0981B3D83Q26798470-B795A138-7659-4CFE-A97E-27DFE9EAF003Q26859275-9862033B-F101-4216-BA07-F59DFFB89392Q27010653-A66F2BDC-54E2-4E0B-8D46-70F05AFE3D11Q27022721-6747CD29-9F52-4ADF-8493-CE98A688B19DQ28386081-857AD13A-EBC9-4067-AA0C-F6E4C4265FA7Q28533457-AE894829-6080-4A87-9109-41EC5A1AC951Q30235355-E74E0ECF-52F2-4537-BD6A-BA23B4B415A5Q30240070-DA3D2F86-96A9-4DA7-9829-E0E34C53E7FBQ30884173-9BC8C0B0-76BF-4B96-B9BF-94F3B48A1499Q33518976-2765FB89-9471-47A0-AC8D-D16DAA3608E9Q33573495-D2CB0CFF-BD63-441A-A2B0-748053136CA3Q33687277-8ED9EE05-16A5-42FE-A63B-D8CB750A081EQ33707461-BBDE5D1C-7477-4A11-8BB6-4A408582F2BCQ33764777-072E19EB-1784-4A4B-ADC6-AAE12FEB6538Q33766984-B8FC8A74-8AC8-4E43-956B-061B2F4BEBC3Q33767314-69E323C0-5573-4273-9EB6-5FE7A1C827E8Q33806889-15BF5ED2-C7BD-49A3-AE64-24547269C6FBQ33905984-8993F8B4-A86F-4C7D-9CBD-6C8A6DDD99DDQ33945004-D44E0BAD-BDBC-4608-B4A9-8088CAC01FBFQ33965296-207BDA46-F034-4A8A-A6E2-24161F9F5EE6Q34002840-8DC5531D-5B51-4825-ACE2-DE58D71FDE3CQ34272562-2E58C194-DCEA-440B-8B65-6F4D6FBF848AQ34396189-8C533163-6323-427F-834F-7F31BD898353Q34405381-1E948EAE-DFAD-4224-85F5-B03BEF352B96Q34549290-1C499CBD-7932-4FC3-8AE1-F490472990BEQ35061893-2D1A96BC-D05A-4C6E-A95A-FF878206A433Q35676039-4AC211A1-C6DA-4914-A8FA-453093D71C60Q35864056-D86EC283-D8EC-4EE1-A7B7-028593050962Q35981569-85F25F7E-2B86-4A88-87E3-C320CACCEDC0Q36063049-A50F3862-34AE-4D4A-9EC1-C664E5E97C55Q36093703-F463AB7A-B6D3-4620-A27D-A613A2A4F03EQ36333552-D8C5700D-8EA9-4101-BB2A-2FD445833AFDQ36339459-02A17732-EC2E-4579-9D47-15A4E582523FQ36402045-8DF6BC36-DA96-4D82-9E91-B3A6D796E75AQ36431041-F9850E13-88A6-45AA-8DD4-C2BAE3B35165Q36530726-EE6EA48A-3FDA-4457-9B13-9847B6AC04C3Q36811828-D6996693-29EE-4127-B410-3DA0B5C3DB52Q36838132-D2C951CB-8E61-4BD9-A518-C699FCDC606E
P2860
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prognostic impact of elevated ...... tive stem cell transplantation
@ast
Prognostic impact of elevated ...... tive stem cell transplantation
@en
type
label
Prognostic impact of elevated ...... tive stem cell transplantation
@ast
Prognostic impact of elevated ...... tive stem cell transplantation
@en
prefLabel
Prognostic impact of elevated ...... tive stem cell transplantation
@ast
Prognostic impact of elevated ...... tive stem cell transplantation
@en
P2093
P2860
P1433
P1476
Prognostic impact of elevated ...... tive stem cell transplantation
@en
P2093
Corey S Cutler
Edwin P Alyea
Haesook T Kim
John Koreth
Joseph H Antin
Philippe Armand
Robert J Soiffer
Vincent T Ho
P2860
P304
P356
10.1182/BLOOD-2006-10-054924
P407
P577
2007-01-18T00:00:00Z